Prescient Therapeutics Offers Shares at 16.7% Discount Until July 25
Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.
- SPP closing date extended to July 25, 2025
- Shares offered at 16.7% discount to 15-day VWAP of $0.040
- Eligible shareholders can apply for up to A$30,000 in new shares
- Strong shareholder and director participation reported
- Investor briefing scheduled to discuss Phase 2b clinical progress
Share Purchase Plan Extension
Prescient Therapeutics Limited (ASX, PTX), a clinical-stage oncology company, has announced an extension of its Share Purchase Plan (SPP) closing date from July 22 to July 25, 2025. This decision comes after multiple shareholder requests for additional time to participate. The extension allows eligible shareholders to apply for new fully paid ordinary shares at a discounted price, reinforcing the company’s commitment to broad shareholder engagement.
The SPP offers shares at a 16.7% discount to the volume weighted average price (VWAP) over 15 trading days, set at $0.040 per share. Eligible shareholders as of June 30, 2025, can apply for up to A$30,000 worth of shares, providing an accessible opportunity to increase their stake in Prescient’s promising oncology pipeline.
Strong Support and Director Participation
The company’s board expressed satisfaction with the strong support demonstrated by shareholders to date, noting that all eligible directors have participated in the SPP. This level of insider confidence often signals positive sentiment about the company’s prospects and upcoming milestones.
Prescient’s capital raising through the SPP is a strategic move to underpin its ongoing clinical development programs, including the advancement of PTX-100 and its novel cell therapy platforms. The funds raised will support critical phases of clinical trials and regulatory activities.
Upcoming Investor Engagement and Clinical Milestones
To complement the SPP, Prescient will host a live investor briefing on July 22, 2025, where CEO James McDonnell will discuss the recent initiation of a U.S. clinical site for a Phase 2b registrational study. This milestone is a significant step toward potential regulatory approval and commercialisation of their targeted therapies.
Prescient’s pipeline includes PTX-100, a first-in-class compound targeting key oncogenic pathways, and innovative cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR. These programs are designed to enhance the efficacy and durability of cancer immunotherapies, positioning the company at the forefront of personalised oncology treatment.
Risks and Forward Outlook
While the company is optimistic, it acknowledges the inherent risks in drug development, including clinical trial delays, regulatory hurdles, and the uncertainty of achieving desired safety and efficacy outcomes. Investors are cautioned to consider these factors alongside the promising clinical progress.
The extended SPP and upcoming investor briefing provide a timely opportunity for shareholders and potential investors to assess Prescient’s strategic direction and clinical advancements as it moves closer to pivotal trial readouts.
Bottom Line?
Prescient’s SPP extension and clinical milestones set the stage for a critical phase in its oncology journey, with investor interest likely to intensify.
Questions in the middle?
- What will be the final subscription amount and total funds raised through the SPP?
- How will the Phase 2b trial results impact Prescient’s valuation and regulatory prospects?
- What are the timelines and expectations for the commercialisation of PTX-100 and cell therapy platforms?
